ESMO News

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

The ESMO TAT Asia Congress 2025 is placed to become a catalyst for global collaboration and innovation in oncology, recognising the region’s growing leadership in early drug development and creating new opportunities for cross-border partnerships.

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

noreply@esmo.org — Fri, 18 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the KEYNOTE-689 study

EMA Recommends Extending Indications for Durvalumab

noreply@esmo.org — Thu, 17 Jul 2025 07:07:00 +00:00

New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR, China, 18-20 July

noreply@esmo.org — Wed, 16 Jul 2025 17:07:00 +00:00

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression

noreply@esmo.org — Wed, 16 Jul 2025 07:07:00 +00:00

Findings from the ATRACTIB study

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer

noreply@esmo.org — Tue, 15 Jul 2025 07:07:00 +00:00

Findings from the POD1UM-303/InterAACT-2 study

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC

noreply@esmo.org — Mon, 14 Jul 2025 07:07:00 +00:00

Findings from the IMforte study

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 11 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies

EMA Recommends Extension of Indications for Cabozantinib

noreply@esmo.org — Thu, 10 Jul 2025 07:07:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic NETs

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC

noreply@esmo.org — Wed, 09 Jul 2025 07:07:00 +00:00

Findings from the SERENA-6 study

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Tue, 08 Jul 2025 07:07:00 +00:00

Findings from the MIDAS study

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC

noreply@esmo.org — Mon, 07 Jul 2025 07:07:00 +00:00

Findings from the KEYNOTE-689 study

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe

noreply@esmo.org — Fri, 04 Jul 2025 08:07:00 +00:00

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

noreply@esmo.org — Fri, 04 Jul 2025 07:07:00 +00:00

Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

noreply@esmo.org — Thu, 03 Jul 2025 07:07:00 +00:00

It is intended for the treatment of adult patients with progressing desmoid tumours

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Wed, 02 Jul 2025 07:07:00 +00:00

Findings from the DESTINY-Gastric04 study

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation

noreply@esmo.org — Tue, 01 Jul 2025 08:07:00 +00:00

Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1

noreply@esmo.org — Tue, 01 Jul 2025 07:07:00 +00:00

Findings from the KOMET study

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the INAVO120 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study